Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

Jennifer L. Osborn; Gary G. Schwartz; David C. Smith; Robert Bahnson; Roger Day; Donald L. Trump

doi:10.1016/1078-1439(95)00061-5

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

Jennifer L. Osborn, Gary G. Schwartz, David C. Smith, Robert Bahnson, Roger Day, Donald L. Trump

Research output: Contribution to journal › Article › peer-review

129 Scopus citations

Abstract

Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D₃ in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)₂D₃) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)₂D₃ was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)₂D₃ given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)₂D₃ is limited by hypercalcemia.

Original language	English (US)
Pages (from-to)	195-198
Number of pages	4
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	1
Issue number	5
DOIs	https://doi.org/10.1016/1078-1439(95)00061-5
State	Published - 1995
Externally published	Yes

Keywords

1
25(OH)D
Prostate cancer
Vitamin D
calcitriol
therapeutics

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/1078-1439(95)00061-5

Fingerprint Dive into the research topics of 'Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer'. Together they form a unique fingerprint.

Cite this

@article{048721bfb23244df8ecf23d5ad3e4df4,

title = "Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer",

abstract = "Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D3 in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)2D3) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)2D3 was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)2D3 given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)2D3 is limited by hypercalcemia.",

keywords = "1, 25(OH)D, Prostate cancer, Vitamin D, calcitriol, therapeutics",

author = "Osborn, {Jennifer L.} and Schwartz, {Gary G.} and Smith, {David C.} and Robert Bahnson and Roger Day and Trump, {Donald L.}",

year = "1995",

doi = "10.1016/1078-1439(95)00061-5",

language = "English (US)",

volume = "1",

pages = "195--198",

journal = "Urologic Oncology",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

AU - Osborn, Jennifer L.

AU - Schwartz, Gary G.

AU - Smith, David C.

AU - Bahnson, Robert

AU - Day, Roger

AU - Trump, Donald L.

PY - 1995

Y1 - 1995

N2 - Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D3 in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)2D3) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)2D3 was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)2D3 given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)2D3 is limited by hypercalcemia.

AB - Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D3 in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)2D3) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)2D3 was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)2D3 given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)2D3 is limited by hypercalcemia.

KW - 1

KW - 25(OH)D

KW - Prostate cancer

KW - Vitamin D

KW - calcitriol

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=0001013226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001013226&partnerID=8YFLogxK

U2 - 10.1016/1078-1439(95)00061-5

DO - 10.1016/1078-1439(95)00061-5

M3 - Article

AN - SCOPUS:0001013226

VL - 1

SP - 195

EP - 198

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 5

ER -